Jeffrey Alan Hawkins Sells 11,310 Shares of Quantum-Si (NASDAQ:QSI) Stock

Quantum-Si Incorporated (NASDAQ:QSI) CEO Jeffrey Alan Hawkins sold 11,310 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $0.96, for a total value of $10,857.60. Following the transaction, the chief executive officer directly owned 3,681,113 shares of the company’s stock, valued at approximately $3,533,868.48. This represents a 0.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Jeffrey Alan Hawkins also recently made the following trade(s):

• On Tuesday, June 23rd, Jeffrey Alan Hawkins sold 11,311 shares of Quantum-Si stock. The stock was sold at an average price of $0.90, for a total transaction of $10,179.90.
• On Monday, April 20th, Jeffrey Alan Hawkins sold 83,712 shares of Quantum-Si stock. The stock was sold at an average price of $1.01, for a total transaction of $84,549.12.

Quantum-Si Price Performance

NASDAQ:QSI opened at $0.86 on Friday. Quantum-Si Incorporated has a 12 month low of $0.69 and a 12 month high of $3.10. The firm has a market capitalization of $186.69 million, a PE ratio of -1.68 and a beta of 3.18. The business’s fifty day moving average price is $0.99 and its 200 day moving average price is $1.03.

Quantum-Si (NASDAQ:QSI) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. The company had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.30 million. Quantum-Si had a negative return on equity of 47.35% and a negative net margin of 5,605.88%. As a group, equities analysts anticipate that Quantum-Si Incorporated will post -0.49 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Quantum-Si in a research note on Friday, March 27th. Canaccord Genuity Group reduced their price objective on shares of Quantum-Si from $1.50 to $1.00 and set a “hold” rating for the company in a research report on Wednesday, March 4th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Quantum-Si currently has a consensus rating of “Reduce” and an average target price of $1.00.

Institutional Trading of Quantum-Si

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Quantum-Si by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 8,714,507 shares of the company’s stock valued at $12,287,000 after purchasing an additional 44,846 shares during the period. Geode Capital Management LLC increased its position in Quantum-Si by 9.8% during the fourth quarter. Geode Capital Management LLC now owns 4,114,375 shares of the company’s stock worth $4,527,000 after buying an additional 367,206 shares during the period. Millennium Management LLC acquired a new position in Quantum-Si during the first quarter worth approximately $4,721,000. State Street Corp lifted its stake in Quantum-Si by 26.5% in the fourth quarter. State Street Corp now owns 3,562,721 shares of the company’s stock valued at $3,919,000 after buying an additional 745,231 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in Quantum-Si in the third quarter valued at approximately $865,000. 39.90% of the stock is owned by hedge funds and other institutional investors.

About Quantum-Si

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.